NGL Fine-Chem Limited share price
NSE: NGLFINE · ISIN INE887E01022
Key numbers
- Market cap
- ₹ 1,795 Cr
- Current price
- ₹ 2,906.10
- 52-week high / low
- ₹ 3,602 / 1,271
- Stock P/E
- 31.4
- Book value
- ₹ 532.9
- Dividend yield
- 0.06%
- ROCE
- 16.7%
- ROE
- 15.7%
- Debt to equity
- 0.37
- Sales growth (3 yrs)
- 21.8%
- Profit growth (3 yrs)
- 32.9%
- 1-year return
- 99.7%
About NGL Fine-Chem Limited
NGL Fine-Chem Limited develops and manufactures veterinary APIs, human APIs, intermediates, and finished dosage forms in India, Europe, the Asia Pacific, the United States, and internationally. The company offers afoxolaner, amitraz, atovaquone, buparvaquone, butaphosphan, carprofen, clorsulon, closantel base, closantel sodium, decoquinate, diminazene diaceturate, febantel, fenbendazole, fluazuron, flumethrin, flunixin meglumine, fluralaner, halquinol, homidium chloride, imidocarb dipropionate, isometamidium chlroide HCl, lotilaner, marbofloxacin, maropitant citrate monohydrate, nitroscanate, nitroxynil, oclacitinib maleate, oxfendazole, parvaquone, permethrin, phenazone, ponazuril, praziquantel, ractopamine HCL, rafoxanide, ricobendazole, r-praziquantel, sarolaner, s-methoprene, toldimfos sodium, toltrazuril, triclabendazole, xylazine base, xylazine HCl, and zilpaterol. It also provides anthelmintics, antiprotozoals, ectoparasiticides, phosphorus supplements, coccidiostats, and non-steroidal anti-inflammatory drugs. In addition, the company offers atovaquone, nitazoxanide, and praziquantel for anti malarial, anti diarrheal, and anthelmintic therapeutic categories. Further, it…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 104 | 120 | 128 | 149 | 139 |
| Operating profit | 11 | 17 | 22 | 21 | 23 |
| Net profit | 9 | 10 | 16 | 13 | 18 |
| EPS (₹) | 14.96 | 15.58 | 25.40 | 21.83 | 29.78 |
Peers in Drug Manufacturers - General
Data for information only, not investment advice. Prices end of day.